BeOne Medicines (NASDAQ:ONC) Stock Gets Price Target Bump from Wells Fargo & Company

Posted by George Bondi on Nov 8th, 2026

BeOne Medicines (NASDAQ:ONC – Get Free Report) had its price objective hoisted by investment analysts at Wells Fargo & Company from $400.00 to $435.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target points to a potential upside of 6.89% from the company’s current price.

Several other research analysts have also commented on the stock. Zacks Research lowered shares of BeOne Medicines from a “strong-buy” rating to a “hold” rating in a report on Monday, October 5th. Nomura lifted their target price on shares of BeOne Medicines from $454.75 to $484.91 and gave the company a “buy” rating in a research note on Thursday, August 6th. Guggenheim boosted their price target on shares of BeOne Medicines from $420.00 to $430.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. TD Cowen boosted their price target on shares of BeOne Medicines from $424.00 to $454.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $470.00 price target on shares of BeOne Medicines in a research note on Thursday. Sixteen research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $434.79.

View Our Latest Stock Analysis on ONC

BeOne Medicines Stock Performance

Shares of ONC stock opened at $406.96 on Friday. The stock has a fifty day moving average of $363.49 and a 200 day moving average of $326.34. BeOne Medicines has a 52 week low of $253.95 and a 52 week high of $410.71. The firm has a market capitalization of $44.68 billion, a price-to-earnings ratio of 51.71 and a beta of 0.63. The company has a quick ratio of 3.06, a current ratio of 3.40 and a debt-to-equity ratio of 0.17.

BeOne Medicines (NASDAQ:ONC – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported $3.64 earnings per share for the quarter, beating the consensus estimate of $2.34 by $1.30. The business had revenue of $1.89 billion for the quarter, compared to analysts’ expectations of $1.76 billion. BeOne Medicines had a net margin of 13.86% and a return on equity of 20.09%. As a group, research analysts expect that BeOne Medicines will post 8.99 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Titus B. Ball sold 132 shares of the company’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $355.86, for a total value of $46,973.52. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John Oyler sold 54,892 shares of the stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $358.15, for a total value of $19,659,569.80. Following the completion of the transaction, the chief executive officer owned 240,743 shares of the company’s stock, valued at approximately $86,222,105.45. This trade represents a 18.57% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 376,373 shares of company stock valued at $134,848,154 over the last 90 days. 6.19% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Fisher Asset Management LLC bought a new stake in BeOne Medicines during the third quarter worth about $367,000. Russell Investments Group Ltd. grew its holdings in BeOne Medicines by 34.2% in the third quarter. Russell Investments Group Ltd. now owns 29,621 shares of the company’s stock worth $10,839,000 after purchasing an additional 7,556 shares during the period. Jefferies Financial Group Inc. grew its holdings in BeOne Medicines by 184.4% in the third quarter. Jefferies Financial Group Inc. now owns 18,200 shares of the company’s stock worth $6,660,000 after purchasing an additional 11,800 shares during the period. Knights of Columbus Asset Advisors LLC bought a new position in shares of BeOne Medicines during the third quarter valued at approximately $106,000. Finally, Allspring Global Investments Holdings LLC increased its stake in shares of BeOne Medicines by 22.6% during the third quarter. Allspring Global Investments Holdings LLC now owns 966 shares of the company’s stock valued at $340,000 after purchasing an additional 178 shares in the last quarter. 48.55% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about BeOne Medicines

Here are the key news stories impacting BeOne Medicines this week:

Positive Sentiment: BeOne reported Q3 EPS of $3.64, above the $2.34 consensus, and revenue of $1.89 billion, topping estimates of $1.76 billion. The company also raised its 2026 revenue guidance, supporting a stronger outlook. Q3 earnings and guidance
Positive Sentiment: The FDA granted priority review to a BRUKINSA combination for first-line mantle cell lymphoma. A faster review could bring a potential label expansion sooner, though approval is not guaranteed. FDA priority review
Positive Sentiment: Several firms raised price targets while maintaining bullish ratings: RBC to $465, Citizens JMP to $463, Truist to $448, Barclays to $446, and Wells Fargo to $435. The revisions signal continued analyst confidence in BeOne’s prospects. RBC rating information Citizens JMP rating information Truist rating information Barclays rating information Wells Fargo rating information

About BeOne Medicines

(Get Free Report)

BeOne Medicines, formerly known as BeiGene, is a global biotechnology company focused on discovering, developing, manufacturing and commercializing cancer medicines. Founded in Beijing in 2010, the company has expanded its research and commercial operations across multiple regions, including the United States, Europe and Asia.

Its marketed products include Brukinsa (zanubrutinib), a targeted therapy for certain blood cancers, and Tevimbra (tislelizumab), an immunotherapy used to treat several types of cancer.